BridgeBio Pharma, Inc. Stock Analysis & AI Score
BridgeBio Pharma, Inc. (BBIO) has an ST Score of 56.2 (B-), driven by its Sentiment (A+) and held back by its Financial Strength (C). Analysts rate it Buy with a $110.09 price target (+66.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
BridgeBio Pharma, Inc. (BBIO) has an ST Score of 56.2 (B-), driven by its Sentiment (A+) and held back by its Financial Strength (C). Analysts rate it Buy with a $110.09 price target (+66.1% upside).
- Strongest
- SentimentA+
- Weakest
- Financial StrengthC
All factor grades
- SentimentA+
- ValuationA-
- MomentumB
- ForecastB-
- GrowthC+
- ProfitabilityC
- Financial StrengthC
- Piotroski3/9
Contact
BBIO stock: frequently asked questions
What is BBIO's ST Score?
BridgeBio Pharma, Inc. (BBIO) has an ST Score of 56.2 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is BBIO a buy, hold, or sell?
Analysts rate BBIO a Buy, with a price target of $110.09 (+66.1% vs the current price). Our ST Score grades it B- (56.2/100). The ST Score is a data-driven signal, not a recommendation.
What are BBIO's factor grades?
Valuation A-, Profitability C, Financial Strength C, Momentum B, Growth C+, Forecast B-, Sentiment A+.
What is BBIO's valuation grade?
BridgeBio Pharma, Inc. (BBIO) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is BBIO's growth grade?
BridgeBio Pharma, Inc. (BBIO) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is BBIO's profitability grade?
BridgeBio Pharma, Inc. (BBIO) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is BBIO's financial strength grade?
BridgeBio Pharma, Inc. (BBIO) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for BBIO?
The average analyst price target for BridgeBio Pharma, Inc. (BBIO) is $110.09 from 27 analysts, which is +66.1% versus the recent price of $66.28.
What is BBIO's Piotroski score?
BridgeBio Pharma, Inc. (BBIO) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.